Validation of the VE1 immunostain for the BRAFV600E mutation in melanoma
- 10 June 2014
- journal article
- research article
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 41 (9), 724-732
- https://doi.org/10.1111/cup.12364
Abstract
Background BRAF mutation status, and therefore eligibility for BRAF inhibitors, is currently determined by sequencing methods. We assessed the validity of VE1, a monoclonal antibody against the BRAF V600E mutant protein, in the detection of mutant BRAF V600E melanomas as classified by DNA pyrosequencing. Methods The cases were 76 metastatic melanoma patients with only one known primary melanoma who had had BRAF codon 600 pyrosequencing of either their primary (n = 19), metastatic (n = 57) melanoma, or both (n = 17). All melanomas (n = 93) were immunostained with the BRAF VE1 antibody using a red detection system. The staining intensity of these specimens was scored from 0 to 3+ by a dermatopathologist. Scores of 0 and 1+ were considered as negative staining while scores of 2+ and 3+ were considered positive. Results The VE1 antibody showed a sensitivity of 85% and a specificity of 100% as compared to DNA pyrosequencing results. There was 100% concordance between VE1 immunostaining of primary and metastatic melanomas from the same patient. V600K, V600Q, and V600R BRAF melanomas did not positively stain with VE1. Conclusions This hospital‐based study finds high sensitivity and specificity for the BRAF VE1 immunostain in comparison to pyrosequencing in detection of BRAF V600E in melanomas.Keywords
Funding Information
- National Cancer Institute (R01 CA112243)
This publication has 32 references indexed in Scilit:
- Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytomaActa Neuropathologica, 2011
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Research, 2010
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032Journal of Translational Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature, 2010
- NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencingMelanoma Research, 2006
- NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.2003
- High frequency of BRAF mutations in neviNature Genetics, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytesThe EMBO Journal, 2000